Emerging PEGylated drugs

被引:228
作者
Kang, Jung Seok [1 ]
DeLuca, Patrick P. [2 ]
Lee, Kang Choon [1 ]
机构
[1] Sungkyunkwan Univ, Coll Pharm, Drug Targeting Lab, Suwon 440746, South Korea
[2] Univ Kentucky, Coll Pharm, Lexington, KY 40536 USA
关键词
PEG conjugates; PEGylated drugs; PEGylation; peptide and protein drugs; CHRONIC HEPATITIS-C; ADENOSINE-DEAMINASE DEFICIENCY; SITE-SPECIFIC PEGYLATION; HORMONE-RELEASING-FACTOR; POLYETHYLENE-GLYCOL; ARGININE DEIMINASE; COST-EFFECTIVENESS; SALMON-CALCITONIN; MACROMOLECULAR THERAPEUTICS; HEPATOCELLULAR-CARCINOMA;
D O I
10.1517/14728210902907847
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
PEGylation is a pharmaceutical technology that involves the covalent attachment of polyethylene glycol (PEG) to a drug to improve its pharmacokinetic, pharmacodynamic, and immunological profiles, and thus, enhance its therapeutic effect. Currently, PEGylation is used to modify proteins, peptides, oligonucleotides, antibody fragments, and small organic molecules. Research groups are striving to improve the consistencies of PEGylated drugs and to PEGylate commercialized proteins and small organic molecules. Furthermore, the PEGylations of novel medications, like oligonucleotides and antibody fragments, are being pursued to improve their bioavailabilities. This active research in the PEGylation field and the continued growth of the biopharmaceutical market predicts that PEGylated drugs have a bright future.
引用
收藏
页码:363 / 380
页数:18
相关论文
共 111 条
[1]
ABUCHOWSKI A, 1977, J BIOL CHEM, V252, P3582
[2]
*AM, 2008, AM HOM INF
[3]
*AMG PROD INF, 2008, NEUL BRAND PROF ANN
[4]
PEGylation governs the disposition and metabolism of irinotecan following administration of a novel PEG-irinotecan conjugate [J].
Antonian, L. ;
Burton, K. ;
Goodin, R. ;
Bentley, M. ;
Eldon, M. A. .
EJC SUPPLEMENTS, 2007, 5 (04) :115-115
[5]
ATHWAL D, 2001, Patent No. 0194585
[6]
A SHORT METHOD FOR PURIFICATION OF ARGINASE FROM OX LIVER [J].
BACH, SJ ;
HAWKINS, RA ;
SWAINE, D .
BIOCHEMICAL JOURNAL, 1963, 89 (02) :263-&
[7]
Polyethylene glycol-conjugated pharmaceutical proteins [J].
Bailon, P ;
Berthold, W .
PHARMACEUTICAL SCIENCE & TECHNOLOGY TODAY, 1998, 1 (08) :352-356
[8]
Rational design of a potent, long-lasting form of interferon:: A 40 kDa branched polyethylene glycol-conjugated interferon α-2a for the treatment of hepatitis C [J].
Bailon, P ;
Palleroni, A ;
Schaffer, CA ;
Spence, CL ;
Fung, WJ ;
Porter, JE ;
Ehrlich, GK ;
Pan, W ;
Xu, ZX ;
Modi, MW ;
Farid, A ;
Berthold, W .
BIOCONJUGATE CHEMISTRY, 2001, 12 (02) :195-202
[9]
Biggers K, 2008, CURR OPIN INVEST DR, V9, P422
[10]
Certolizumab pegol in Crohn's disease [J].
Blick, Stephanie K. A. ;
Curran, Monique P. .
BIODRUGS, 2007, 21 (03) :195-201